Skip to main content

Research News

  • Bariatric surgery linked to heart health improvements in people with severe obesity

    Bariatric surgery may result in significant cardiometabolic improvements, particularly among younger, female, or white people and those without comorbidities, according to new research published in the Journal of the Endocrine Society.

  • Heart Health Declines Rapidly After Menopause

    A woman’s cardiovascular risk can rise sharply after she goes through menopause, quickly catching up to men of a similar age and health profile, according to new findings presented at the American College of Cardiology’s Annual Scientific Session. Researchers said the study underscores the importance of recognizing and addressing early warning signs of heart disease risk in women as they lose the protective effects of estrogen after menopause.

  • Imfinzi significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

    Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following concurrent chemoradiotherapy (cCRT) compared to placebo after cCRT.

  • Researchers uncover potential treatment targets for Zika virus-related eye abnormalities

    A groundbreaking study published in the journal iScience presents crucial insights into the ocular effects of Zika virus infection during pregnancy and offers promising avenues for therapeutic intervention.

  • Mayo Clinic scientists pioneer immunotherapy technique for autoimmune diseases

    Mayo Clinic scientists have developed an immunotherapy strategy that potentially lays the groundwork for treating a spectrum of autoimmune diseases.

    The new technique, detailed in a preclinical study published in Nature Biomedical Engineering, involves combining chimeric antigen receptors (CAR) with mesenchymal stromal cells (MSC), resulting in engineered stem cells known as CAR-MSCs.

  • Simulations reveal mechanism behind protein build-up in Parkinson's disease

    Researchers have used computational models to understand what drives the accumulation of alpha-synuclein protein, a key culprit in the development of Parkinson’s disease.

  • Johns Hopkins Investigators Develop Novel Treatment for T-cell Leukemias and Lymphomas

    A novel treatment for leukemias and lymphomas that arise from immune system T cells,  developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors.

  • Single genomic test promises accelerated diagnoses for rare genetic diseases

    A new approach to analysing exome sequencing data reliably detects large-scale genetic changes and could reduce the number of genetic tests a child might need. A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children. This shift could enable earlier diagnoses for families and save the NHS vital resources.

  • Rutgers Racing to Discover a Better Paxlovid

    Researchers from Rutgers Health believe they are among the leaders in a race to find an oral COVID-19 treatment to supplement or replace Paxlovid – an antiviral medication that helps keep high-risk patients out of the hospital.

    Their report, published in Science, shows that an alternative medication, a viral papain-like protease inhibitor, inhibits disease progression in animals, a necessary step before human drug trials.

  • COVID-19 Antibody Discovery Could Explain Long COVID

    UVA Health researchers have discovered a potential explanation for some of the most perplexing mysteries of COVID-19 and long COVID. The surprising findings could lead to new treatments for the difficult acute effects of COVID-19, long COVID and possibly other viruses.

Subscribe to Research News